Ironwood Pharmaceuticals Inc (FRA:I76)
€ 4.5 -0.04 (-0.88%) Market Cap: 713.95 Mil Enterprise Value: 1.21 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Ironwood Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 01:00PM GMT
Release Date Price: €8.25 (+1.23%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. I'm David Lebowitz, one of the biotechnology analysts at Morgan Stanley. Before I get started, I have to go through the requisite disclosures. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

I'd like to welcome you all this morning to the Morgan Stanley 18th Annual Global Healthcare Conference. In this session, I have with us from Ironwood Pharmaceuticals, CEO, Mark Mallon; and President, Tom McCourt. This is a company that's been around for a while. They are -- they sell a drug called LINZESS for the treatment of constipation. And I guess before

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot